Efficacy and Safety of Fire Needle Therapy Combined With Cortex Phellodendri Compound Fluid Wet Compress for Acute Herpes Zoster: a Randomized Controlled Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- males and females, aged 18-80 years old;
- diagnosed as acute HZ with the course of disease within 7 days;
- without history of other treatment before enrollment.
Exclusion Criteria:
- specific types of HZ, including Ramsay Hunt Syndrom, ophthalmic, disseminated, deep, purpuric and central nervous system HZ;
- pregnancy and lactation;
- allergic to the related Chinese herbals;
- patients with contraindications to penciclovir, mecobalamin and pregabalin; (e) history of hypertrophic scar or keloid;
(f) severe cardiovascular, cerebrovascular, digestive, urinary or hematopoietic disease; (g) mental disease; (h) coagulation disorders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: treated group
The patients received fire needle (5 sessions, every other day) combined with CPCF wet compress treatment (3 times/day, 10 days) in addition to the basic treatment of the control group.
|
At the beginning of the fire needle therapy, the patient was instructed to exposure the lesion in a comfortable position.
And the Ashi point (lesion area) was disinfected with iodophor.
The 95% alcohol lamp was lit and held by the left hand.
Then the needle was held by the right hand in the outer flame of the alcohol lamp to heat the needle body, making the tip of the needle whiten.
Subsequently, the needle was quickly and accurately puncted into the base of the herpes at a depth of about 2-5 mm, straight in and out.
According to the number of herpes, the early-onset herpes was puncted first, and about 5 to 10 blisters were selected for each puncture.
The acupuncture was performed 1-5 times according to the size of the herpes.
The treatment was performed once every other day for total 5 sessions.
For the Chinese herbal wet compress treatment, CPCF (Shandong Hanfang Pharmaceutical Co., LTD.) was decocted using forsythia, honeysuckle, phellodendron, dandelion, and centipede.
Appropriate amount of liquid was diluted with 5 times the volume of water.
Then according to the area of skin lesions, several pieces of medical fat-free cotton gauze with thickness of 8 layers were put into the liquid completely wet.
After wringing out to a semi-dry state, the gauze was applied to the lesion for 15 minutes/time, 3 times a day, for 10 days.
The basic treatment consisted of penciclovir 0.5g/time per day intravenously, mecobalamin 0.5mg/time three times a day orally and pregabalin 75mg/time twice a day orally for 10 days.
|
|
Experimental: control group
The control group received basic treatment, which consisted of penciclovir 0.5g/time per day intravenously, mecobalamin 0.5mg/time three times a day orally and pregabalin 75mg/time twice a day orally for 10 days.
|
The basic treatment consisted of penciclovir 0.5g/time per day intravenously, mecobalamin 0.5mg/time three times a day orally and pregabalin 75mg/time twice a day orally for 10 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
herpes zoster symptom and sign quantitative scoring scale
Time Frame: From enrollment to day 10
|
The degree of the clinical symptoms and signs of HZ (including local pain, local itching, burning sensation, papular erythema, number of blisters, number of blister clusters, herpes character, ulcer, fever, local lymph node enlargement, and skin lesion area change) were divided into four grades: 0 (none), 1 (mild), 2 (moderate), and 3 (severe).
|
From enrollment to day 10
|
|
lesion improvement index n
Time Frame: From enrollment to day 10
|
The lesion improvement index n was calculated by the formula: n (%) = (symptom and sign quantitative score at baseline - symptom and sign quantitative score at 10 days)/symptom and sign quantitative score at baselin ×100%.
|
From enrollment to day 10
|
|
the total improved rate
Time Frame: From enrollment to day 10
|
The clinical improvement was graded as follows: clinical cure (n≥90%), significant improvement (70%≤n<90%), moderate improvement (30%≤n<70%), no improvement (n < 30%).
The total improved rate was calculated as cases of (clinical cure + significant improvement + moderate improvement)/total cases×100%.
|
From enrollment to day 10
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
questionnaire of Dermatology Life Quality Index
Time Frame: From enrollment to day 10
|
From enrollment to day 10
|
|
|
Pittsburgh sleep quality index
Time Frame: From enrollment to day 10
|
From enrollment to day 10
|
|
|
Hamilton Anxiety Scale
Time Frame: From enrollment to day 10
|
From enrollment to day 10
|
|
|
Visual analog scale
Time Frame: From enrollment to day 10
|
The pain intensity due to HZ was evaluated by a visual analog scale (VAS) ranging from 0 to 10 (0: no pain, 1-3: mild, 4-6: moderate, 7-10: severe) at day 0 and day 10.
|
From enrollment to day 10
|
|
incidence of postherpetic neuralgia
Time Frame: From enrollment to day 90
|
The incidence of postherpetic neuralgia was analysed at day 90.
|
From enrollment to day 90
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Weihui Zeng, Second Affiliated Hospital of Xi'an JiaoTong University
Publications and helpful links
General Publications
- Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses. 2022 Jan 19;14(2):192. doi: 10.3390/v14020192.
- Zeng JC, Liao YZ, Li JJ, Lu LH, Li HZ, Lu LM, Li QJ, Li LX, Wang SX, Lin GH. [Clinical efficacy of fire needling combined with cupping therapy on herpes zoster of acute stage and the effect on Th17/Treg cellular immune balance]. Zhongguo Zhen Jiu. 2023 Oct 12;43(10):1128-33. doi: 10.13703/j.0255-2930.20221005-k0004. Chinese.
- Zhang Y, Li SH, Yang L, Xu QN, Pei WY, Liang ZH, Liu XH, Yang JJ, Lin GH. [Shallow Fire-needle Acupuncture Stimulation Plus Cupping Relieves Neuralgia and Down-regulates Serum Substance P Level in Patients with Acute Herpes Zoster]. Zhen Ci Yan Jiu. 2018 Aug 25;43(8):492-4. doi: 10.13702/j.1000-0607.170923. Chinese.
- Huang SX, Mao M, Pu JJ, Chen YH, Deng L, Zhao H, Geng MJ, Zhong RF, Guo YJ, Liu ZS, Wang YH, Ye YM, Liu J, Yang T, Zhao AM, Chen XH, Zhu HY, Du YC. [Clinical research on fire filiform needle combined with mild moxibustion for postherpetic neuralgia]. Zhongguo Zhen Jiu. 2014 Mar;34(3):225-9. Chinese.
- Chen J, Luo C, Ju P, Tu S, Shi S, Wang Z, Wu H. A bibliometric analysis and visualization of acupuncture and moxibustion therapy for herpes zoster and postherpetic neuralgia. Skin Res Technol. 2024 Jun;30(6):e13815. doi: 10.1111/srt.13815.
- Dai YX, Yeh FY, Shen YJ, Tai YH, Huang N, Chang YT, Chen TJ, Li CP, Wu CY. Cigarette smoking and risk of herpes zoster: a population-based cohort study in Taiwan. Clin Exp Dermatol. 2021 Oct;46(7):1293-1298. doi: 10.1111/ced.14650. Epub 2021 May 11.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2025514
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.